-+ 0.00%
-+ 0.00%
-+ 0.00%

Onconetix Announces That An Abstract Has Been Accepted For Presentation Titled, "Clinical Performance Of Proclarix In Ruling Out Clinically Insignificant Or No Prostate Cancer: Evaluation In A Danish Cohort" At The 2025 EUA Congress Taking Place March 21-24, 2025, In Madrid, Spain

Benzinga·03/19/2025 12:05:36
Listen to the news

Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that an abstract has been accepted for presentation at the 2025 European Association of Urology (EAU) congress taking place March 21-24, 2025, in Madrid, Spain.

The presentation, titled, "Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort," will highlight Proclarix performance results recently obtained from a study including more than 800 patients recruited from Lillebaelt Hospital - University Hospital of Southern Denmark.